Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonidegib + cemiplimab
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Sonidegib + cemiplimab** is an investigational combination therapy comprised of an oral Hedgehog pathway inhibitor (sonidegib) and an intravenous immune checkpoint inhibitor (cemiplimab)[1][7][3]. Sonidegib selectively inhibits the Smoothened (SMO) receptor, blocking Hedgehog signaling, a driver of basal cell carcinoma pathogenesis. Cemiplimab is a fully human monoclonal IgG4 antibody targeting the Programmed Cell Death Protein 1 (PD-1) receptor on T cells, thus blocking the interaction with PD-L1/PD-L2 ligands and releasing downregulated immune responses against tumor cells[3]. This combination is being evaluated in clinical trials for patients with unresectable, locally advanced, or metastatic basal cell carcinoma, cutaneous squamous cell carcinoma, or synchronous presentations of both, aiming to exploit potential synergism between targeted pathway inhibition and immune checkpoint blockade[1][7].
- Other names
- sonidegib + cemiplimabOdomzo + Libtayo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)SMO (Smoothened)
Beyond the preview
Go deeper on sonidegib + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonidegib + cemiplimab.